Compare NIE & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIE | VALN |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.6M | 536.9M |
| IPO Year | N/A | 2021 |
| Metric | NIE | VALN |
|---|---|---|
| Price | $25.33 | $6.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 78.4K | ★ 144.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.11 | $5.43 |
| 52 Week High | $26.00 | $12.25 |
| Indicator | NIE | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 65.88 | 28.85 |
| Support Level | $24.75 | $5.88 |
| Resistance Level | $25.62 | $6.73 |
| Average True Range (ATR) | 0.40 | 0.26 |
| MACD | 0.23 | 0.10 |
| Stochastic Oscillator | 95.82 | 21.38 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.